{"product_id":"aentrekentrectinib-100mg","title":"Aentrek 100 (entrectinib)","description":"\u003cdiv class=\"collapse-more\"\u003e\r\n\u003ch3\u003e\u003cspan id=\"Non-small_Cell_Lung_Cancer\"\u003eNon-small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003c\/div\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ROS1-positive\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Neurotrophic_Tyrosine_Receptor_Kinase_Gene_Fusion_Solid_Tumors\"\u003eNeurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and progressed following treatment or have no satisfactory alternative therapy\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 400 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 200 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if toxicities persist or recur following 2 dose reductions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Congestive_heart_failure\"\u003eCongestive heart failure\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 2 or 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Central_nervous_system_effects\"\u003eCentral nervous system effects\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIntolerable Grade 2: Withhold until recovered to Grade ≤1; resume at reduced dose, as clinically appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduced dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf resolution occurs within 4 weeks, resume at same dose\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction persists after 4 weeks, permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eFor recurrent Grade 3 events that resolve within 4 weeks, resume at a reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduce dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction does not resolve within 4 weeks or Grade 4 events recurs, permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Elevated_ALT_or_AST\"\u003eElevated ALT or AST\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hyperuricemia\"\u003eHyperuricemia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSymptomatic or Grade 4: Initiate urate-lowering therapy; withhold until improvement of signs or symptoms; resume at same or reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"QTc_500_ms\"\u003eQTc \u0026gt;500 ms\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until QTc interval recovers to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same dose if causes of QT prolongation are identified and corrected\u003c\/li\u003e\r\n \t\u003cli\u003eResume at reduced dose if other causes of QT prolongation are not identified\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Life-threatening_arrhythmia\"\u003eLife-threatening arrhythmia\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTorsade de pointes; polymorphic ventricular tachycardia; signs\/symptoms of serious arrhythmia: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Vision_disorders\"\u003eVision disorders\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade ≥2: Withhold until improvement or stabilization; resume at same dose or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Anemia_or_neutropenia\"\u003eAnemia or neutropenia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade≤2; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Other_clinically_relevant_adverse_reactions\"\u003eOther clinically relevant adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_3_or_4\"\u003eGrade 3 or 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until adverse reaction resolves to Grade 1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same or reduced dose if resolved within 4 weeks\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if adverse reaction does not resolve within 4 weeks or Grade 4 events recurs\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Coadministration_of_moderate_and_strong_CYP3A_inhibitors\"\u003eCoadministration of moderate and strong CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAvoid coadministration\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"If_coadministration_is_unavoidable_reduce_entrectinib_dose_as_follows\"\u003eIf coadministration is unavoidable, reduce entrectinib dose as follows:\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eModerate CYP3A Inhibitors: 200 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eStrong CYP3A Inhibitors: 100 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eAfter discontinuation of strong or moderate CYP3A inhibitor for 3-5 elimination half-lives, resume entrectinib dose taken prior to initiating the CYP3A inhibitor\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl 30 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild (total bilirubin ≤1.5x ULN): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eModerate-to-severe (total bilirubin \u0026gt;1.5x ULN): Not studied; consider risk-benefit profile prior to determining whether to administer therapy to patients with moderate to severe hepatic impairment; monitor for adverse reactions in patients with hepatic impairment more frequently; these patients may be at increased risk for adverse reactions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eNSCLC: Presence of ROS1 rearrangement\u003c\/li\u003e\r\n \t\u003cli\u003eLocally advanced or metastatic solid tumors: Presence of a NTRK gene fusion\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947019307,"sku":"RL1420230901535","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663296906-991924d4ac643fa.jpg?v=1787022083","url":"https:\/\/xomeds.com\/products\/aentrekentrectinib-100mg","provider":"XOMEDS","version":"1.0","type":"link"}